Ketoconazole (Nizoral)

Ketoconazole is an imidazole antifungal medication that has been used in veterinary medicine for several decades to treat a variety of fungal and yeast infections in dogs. As one of the first orally active azole antifungals developed, ketoconazole represented a significant advancement in the treatment of fungal diseases when it became available. While newer antifungal agents such as itraconazole and fluconazole have largely supplanted ketoconazole for many indications due to improved efficacy and safety profiles, ketoconazole remains a useful and cost-effective option for certain conditions, particularly Malassezia yeast infections of the skin and ears. The medication is also notable for its ability to inhibit adrenal steroid synthesis, which has led to its use as an adjunctive treatment for hyperadrenocorticism (Cushing's disease) in dogs.

The mechanism of action of ketoconazole involves inhibition of the fungal cytochrome P450 enzyme lanosterol 14-alpha-demethylase, which is essential for the synthesis of ergosterol, a critical component of fungal cell membranes. By blocking ergosterol production, ketoconazole disrupts the integrity of the fungal cell membrane, leading to leakage of cellular contents and death of the fungal organism. This mechanism is shared with other azole antifungals, but ketoconazole is less potent and has a narrower spectrum of activity compared to newer triazole agents like itraconazole. Importantly, ketoconazole also inhibits mammalian cytochrome P450 enzymes involved in steroid hormone synthesis, which can result in decreased production of cortisol, testosterone, and other hormones, effects that are both a limitation and a therapeutic application of the medication.

Ketoconazole is available in several formulations for use in dogs. Oral tablets, typically in 200 mg strength, are the most common formulation for systemic treatment of fungal infections. Topical formulations including ketoconazole cream and shampoo are available for treatment of localized skin and ear infections. The medication requires an acidic gastric environment for optimal absorption and should be administered with food. Ketoconazole is extensively metabolized by the liver and should be used with caution in dogs with hepatic dysfunction. The medication is typically administered once or twice daily depending on the condition being treated and the individual patient's needs.

The safety profile of ketoconazole in dogs includes several important considerations that have contributed to its declining use compared to newer alternatives. Gastrointestinal side effects including nausea, vomiting, and decreased appetite are relatively common. Hepatotoxicity is a significant concern, particularly with prolonged use, and periodic liver function monitoring is recommended. The medication's effects on steroid hormone synthesis can lead to reproductive disturbances and coat changes in some dogs. Despite these limitations, ketoconazole remains valuable as an affordable antifungal option, particularly for Malassezia infections, and for its unique application in managing Cushing's disease. Veterinary supervision is essential for safe and effective use.

Ketoconazole is primarily used in dogs for the treatment of Malassezia dermatitis and otitis, conditions caused by overgrowth of the yeast Malassezia pachydermatis on the skin and in the ears. Malassezia is a normal inhabitant of canine skin but can proliferate and cause disease when the skin environment is altered by allergies, hormonal disorders, excessive moisture, or other factors. Dogs with Malassezia dermatitis typically present with greasy, malodorous skin, intense itching, hair loss, and thickened, hyperpigmented skin, particularly in areas such as the underarms, groin, neck, and between the toes. Malassezia otitis causes waxy, brown ear discharge with a characteristic yeasty odor. Ketoconazole, administered orally, effectively reduces Malassezia populations and resolves the associated skin and ear disease.

Beyond Malassezia infections, ketoconazole has activity against dermatophyte fungi that cause ringworm (dermatophytosis) in dogs. While it is generally considered less effective than itraconazole or terbinafine for dermatophytosis, ketoconazole remains an option when cost is a significant factor or when other agents are contraindicated. The medication is effective against Microsporum canis, Trichophyton mentagrophytes, and other dermatophyte species that commonly infect dogs. Treatment duration for dermatophytosis with ketoconazole is typically four to eight weeks, continuing until fungal cultures are negative.

Ketoconazole has been used for the treatment of systemic fungal infections in dogs, including blastomycosis, histoplasmosis, cryptococcosis, and coccidioidomycosis, although itraconazole and fluconazole are now generally preferred for these conditions due to greater efficacy and improved safety profiles. When ketoconazole is used for systemic mycoses, it is often combined with amphotericin B initially, as the therapeutic effect of ketoconazole is delayed compared to amphotericin B. Ketoconazole may still be selected for systemic fungal infections in situations where cost considerations are paramount, as it is typically less expensive than newer azole antifungals.

A unique application of ketoconazole in veterinary medicine is its use as an adjunctive treatment for hyperadrenocorticism (Cushing's disease) in dogs. Because ketoconazole inhibits the enzymes involved in cortisol synthesis in the adrenal glands, it can temporarily reduce blood cortisol levels in dogs with this condition. While ketoconazole does not treat the underlying cause of Cushing's disease and is generally considered less effective than trilostane for this purpose, it may be used in certain situations, such as preparing dogs for surgery or as an alternative when other treatments are not tolerated. The dose used for Cushing's disease management is typically higher than that used for antifungal purposes.

The selection of ketoconazole over other antifungal medications depends on various factors. Cost is often a significant consideration, as ketoconazole is generally less expensive than itraconazole and some other alternatives. For Malassezia infections specifically, ketoconazole remains a reasonable first-line option. However, for dermatophytosis and systemic mycoses, the lower efficacy and greater potential for adverse effects compared to newer agents may influence treatment decisions. The veterinarian will consider the specific condition being treated, the dog's overall health status, concurrent medications, and financial factors when determining the most appropriate antifungal therapy.

The dosing of ketoconazole in dogs must be determined by the veterinarian based on the specific condition being treated, the dog's body weight, and individual patient factors. Accurate weight measurement is essential for proper dosing, as ketoconazole is prescribed on a milligram per kilogram basis. Different conditions require different doses and dosing frequencies, so owners should follow the specific instructions provided by the veterinarian rather than relying on general guidelines. Inappropriate dosing can result in treatment failure if the dose is too low or increased risk of adverse effects if the dose is too high.

For treatment of Malassezia dermatitis and otitis, ketoconazole is typically administered at doses ranging from 5-10 mg per kilogram of body weight, given orally once or twice daily. A common protocol involves giving 10 mg per kilogram once daily or 5 mg per kilogram twice daily. Treatment duration for Malassezia infections is usually three to four weeks, though it may be extended based on clinical response. For dermatophytosis, similar doses are used but treatment typically continues for four to eight weeks or until fungal cultures are confirmed negative. For systemic fungal infections, ketoconazole is administered at 10-15 mg per kilogram twice daily, with treatment courses extending for several months.

When ketoconazole is used for management of hyperadrenocorticism, higher doses are typically required. Initial doses may start around 5-10 mg per kilogram twice daily and may be increased based on response, with some protocols using doses up to 15 mg per kilogram twice daily. Treatment for Cushing's disease with ketoconazole requires careful monitoring of cortisol levels and clinical response, with dose adjustments made as needed. The medication does not provide a cure for Cushing's disease and typically must be continued long-term to maintain its effect on cortisol production.

Proper administration of ketoconazole is important for achieving optimal therapeutic results. The medication should be given with food, preferably a meal containing some fat, as this enhances absorption and reduces gastrointestinal upset. An acidic gastric environment is required for ketoconazole to dissolve and be absorbed, so concurrent use of antacids, H2-blockers, or proton pump inhibitors significantly reduces absorption. If acid-reducing medications are necessary, they should be administered at least two hours after ketoconazole to minimize interference with absorption. Tablets should be swallowed whole unless the veterinarian provides different instructions.

If a dose of ketoconazole is missed, it should be given as soon as remembered. If it is almost time for the next scheduled dose, the missed dose should be skipped and the regular schedule resumed. Doses should not be doubled to make up for missed doses. For dogs receiving twice-daily dosing, consistent timing approximately twelve hours apart helps maintain stable drug levels. For once-daily dosing, giving the medication at the same time each day with a meal promotes consistent absorption and helps establish a routine that aids owner compliance.

Completing the full prescribed course of ketoconazole treatment is important for achieving successful outcomes. For fungal infections, treatment should continue for the duration specified by the veterinarian, as stopping prematurely can result in recurrence of infection. For dermatophytosis, treatment should continue until fungal cultures confirm clearance of infection. The veterinarian will schedule follow-up appointments to assess treatment response and determine when therapy can be safely discontinued or if adjustments to the treatment plan are needed.

Ketoconazole has a higher incidence of side effects compared to newer azole antifungals such as itraconazole, which has contributed to its declining use for many indications. Owners should be aware of potential adverse effects and monitor their dogs during treatment. Regular veterinary follow-up, including periodic blood testing, helps identify problems early so that appropriate adjustments can be made. Most side effects are dose-related and reversible upon discontinuation or dose reduction, but some dogs may require a change to alternative antifungal therapy.

The most commonly observed side effects of ketoconazole in dogs are gastrointestinal in nature. Nausea, vomiting, decreased appetite, and diarrhea are frequently reported, particularly at the beginning of treatment or at higher doses. These effects may be minimized by giving the medication with food as directed. If gastrointestinal signs are persistent or severe, the veterinarian may recommend dividing the daily dose into smaller, more frequent doses, reducing the overall dose, or switching to a different medication. Persistent vomiting or complete refusal to eat should be reported to the veterinarian promptly, as these may indicate more serious problems.

Hepatotoxicity is a significant concern with ketoconazole use in dogs and represents the most serious potential adverse effect. Elevated liver enzymes may be detected on routine blood monitoring, indicating hepatic stress. Clinical signs of liver problems may include vomiting, decreased appetite, lethargy, jaundice (yellowing of the gums or whites of the eyes), dark urine, or pale stools. The risk of hepatotoxicity increases with higher doses and longer treatment duration. Baseline liver function testing before starting therapy and periodic monitoring during treatment (typically every two to four weeks) is recommended. If significant liver enzyme elevations develop, the medication should be discontinued and the veterinarian should be contacted.

The effects of ketoconazole on steroid hormone synthesis can lead to several adverse effects. Decreased testosterone production can cause reproductive disturbances in intact male dogs, including decreased libido, reduced sperm production, and testicular atrophy. These effects are typically reversible upon discontinuation of the medication, but ketoconazole should be avoided in breeding males unless the benefits clearly outweigh the risks. Lightening of the coat color has been reported in some dogs receiving ketoconazole, particularly those with red or golden coloring; this effect is also typically reversible. Rarely, signs related to decreased cortisol production may develop, though this is more likely at the higher doses used for Cushing's disease management.

Other potential adverse effects of ketoconazole include skin reactions, hair loss, and dry or thinning coat. Allergic reactions, while uncommon, may manifest as hives, facial swelling, or difficulty breathing and require immediate veterinary attention. If any unusual symptoms develop during ketoconazole treatment, owners should contact their veterinarian. Depending on the nature and severity of adverse effects, the veterinarian may recommend dose reduction, temporary discontinuation, or switching to an alternative antifungal medication.

Ketoconazole should not be used in dogs with known hypersensitivity or allergic reactions to the medication or other azole antifungal drugs. Dogs that have previously experienced adverse reactions to ketoconazole, itraconazole, fluconazole, or related medications may be at risk for cross-reactivity. Any history of medication allergies should be communicated to the veterinarian so that appropriate precautions can be taken. If an allergic reaction occurs during ketoconazole treatment, the medication should be discontinued immediately and veterinary care should be sought.

Significant liver disease is a major contraindication for ketoconazole use in dogs. The medication is extensively metabolized by the liver and has well-documented potential for hepatotoxicity. Dogs with pre-existing hepatic dysfunction may not be able to safely process the drug, and ketoconazole can worsen liver function in these patients. Liver disease may also result in altered drug metabolism and accumulation, increasing the risk of both hepatic and systemic toxicity. Dogs with known liver disease, significantly elevated liver enzymes, or any condition affecting hepatic function should not receive ketoconazole unless no alternatives are available and the potential benefits clearly outweigh the risks. Even then, extremely careful monitoring would be required.

Pregnancy is a contraindication for ketoconazole use due to potential teratogenic effects. The medication has been associated with developmental abnormalities in laboratory animal studies and should be avoided in pregnant dogs. Similarly, ketoconazole is not recommended during lactation, as the drug may be excreted in milk and could affect nursing puppies. Dogs intended for breeding should receive alternative antifungal therapy when possible, and male breeding dogs should not receive ketoconazole due to its effects on testosterone production and sperm quality. Female dogs should not be bred during treatment and for an appropriate period afterward.

Other conditions that may preclude ketoconazole use include thrombocytopenia (low platelet count), as ketoconazole has been associated with decreased platelet counts in some patients. Dogs with adrenal insufficiency (Addison's disease) should not receive ketoconazole due to the medication's suppressive effects on adrenal steroid production. The medication should be used cautiously, if at all, in dogs with cardiac conduction abnormalities, as ketoconazole can prolong the QT interval and potentially cause cardiac arrhythmias. Dogs receiving medications that significantly interact with ketoconazole may need alternative antifungal therapy. A complete medical history and medication list should be provided to the veterinarian so that contraindications can be identified.

Ketoconazole has extensive drug interaction potential, making it essential to inform the veterinarian of all medications, supplements, and products the dog is receiving before starting therapy. The medication is both a substrate and an inhibitor of cytochrome P450 enzymes, particularly CYP3A4, which affects the metabolism of many other drugs. Additionally, ketoconazole absorption is significantly affected by gastric pH, leading to interactions with acid-reducing medications. These interaction potentials require careful review of concurrent medications and may necessitate dose adjustments, timing modifications, or selection of alternative therapies.

Medications that reduce gastric acid significantly decrease ketoconazole absorption. Antacids, histamine-2 receptor blockers (such as famotidine, ranitidine, or cimetidine), and proton pump inhibitors (such as omeprazole) can reduce gastric acidity to a degree that markedly impairs ketoconazole dissolution and absorption. If these medications must be used concurrently, ketoconazole should be administered at least two hours before the acid-reducing medication. Alternatively, the veterinarian may need to select a different antifungal that does not require acidic conditions for absorption. Sucralfate, which coats the stomach lining, can also reduce ketoconazole absorption and should be separated by at least two hours.

As a potent CYP3A4 inhibitor, ketoconazole can significantly increase blood levels of many medications metabolized by this enzyme system. This can lead to enhanced effects or toxicity of the affected drugs. Important interactions include increased levels of benzodiazepines (diazepam, midazolam, alprazolam), which could cause excessive sedation. Cyclosporine levels can be dramatically increased by ketoconazole, potentially requiring significant dose reduction of the immunosuppressant. Ivermectin and other macrocyclic lactones may have increased levels, raising the risk of neurotoxicity, particularly concerning in MDR1-mutant dogs. Cardiac medications including digoxin may have altered levels. Cisapride should not be used with ketoconazole due to the risk of serious cardiac arrhythmias.

Some medications may decrease ketoconazole effectiveness by reducing its absorption or increasing its metabolism. Phenobarbital, phenytoin, and other enzyme-inducing anticonvulsants can increase ketoconazole metabolism and may reduce its antifungal efficacy. Rifampin similarly induces hepatic enzymes and can decrease ketoconazole levels. If these medications must be used together, the veterinarian may need to increase ketoconazole dosing or monitor clinical response more closely. Didanosine and other medications with antacid buffering components can reduce ketoconazole absorption.

Monitoring for drug interactions during ketoconazole therapy is important. Signs of interaction may include unexpected changes in the dog's response to either ketoconazole or concurrent medications, development of new symptoms, excessive sedation if sedatives are being used, or changes in disease control. The veterinarian may recommend more frequent blood testing or clinical monitoring for dogs receiving potentially interacting medications. Any concerning changes should be reported promptly so that appropriate adjustments can be made to the treatment plan.

Several general precautions should be observed when ketoconazole is prescribed for dogs. Accurate weight measurement is essential for proper dosing, and the medication should be administered with food to enhance absorption and minimize gastrointestinal upset. An acidic stomach environment is required for optimal absorption, so timing of ketoconazole administration relative to acid-reducing medications is important if such drugs are being used. Regular follow-up appointments allow the veterinarian to monitor treatment response and assess for adverse effects. Owners should report any concerning symptoms promptly, particularly signs of gastrointestinal upset, decreased appetite, or jaundice.

Liver function monitoring is an important precaution during ketoconazole therapy due to the medication's potential for hepatotoxicity. Baseline liver enzyme testing before starting treatment provides a reference point for comparison. Periodic rechecking of liver enzymes, typically every two to four weeks during treatment, helps identify hepatic problems early. More frequent monitoring may be advisable for dogs receiving higher doses, those on prolonged treatment courses, or those with other risk factors for liver disease. If significant elevations in liver enzymes are detected or if clinical signs of liver problems develop, the medication should be discontinued.

Dogs with the MDR1 (ABCB1) gene mutation require consideration when ketoconazole is prescribed, not because of direct sensitivity to ketoconazole but because of potential interaction with other medications. Ketoconazole can increase levels of drugs that are P-glycoprotein substrates, which could increase toxicity risk in MDR1-mutant dogs receiving ivermectin or similar medications. Breeds commonly affected by the MDR1 mutation include Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, and related breeds. If dogs with the MDR1 mutation require concurrent use of potentially affected medications, particular caution and monitoring are warranted.

Special handling precautions for ketoconazole are not extensive, but general medication safety practices should be followed. The medication should be stored securely away from children and pets. Pregnant women should handle ketoconazole with caution due to potential teratogenic effects and should avoid touching broken or crushed tablets. If tablets need to be split for dosing purposes, this should ideally be done by someone who is not pregnant. Hands should be washed after handling the medication.

Special populations of dogs require additional consideration. Geriatric dogs may have decreased liver function that increases the risk of hepatotoxicity and may require lower doses or more frequent monitoring. Puppies may have immature liver function, and ketoconazole should be used cautiously in young dogs. Dogs with pre-existing conditions affecting the liver, heart, or adrenal glands require careful evaluation before ketoconazole is prescribed. Intact male dogs should be monitored for reproductive effects, and the medication should be avoided in breeding males if possible. Dogs with chronic conditions requiring multiple medications need careful review of drug interactions. The veterinarian will weigh benefits against risks for each individual patient.

Proper storage of ketoconazole tablets helps maintain the medication's stability and effectiveness throughout the treatment course. Tablets should be stored at room temperature, typically between 59°F and 86°F (15°C and 30°C), in a dry location away from excessive moisture and light. The medication should be kept in its original container with the lid tightly closed. Bathroom medicine cabinets are often not ideal storage locations due to humidity. A cool, dry cabinet or drawer away from heat sources provides suitable storage conditions. The expiration date should be checked before use, and expired medication should not be administered.

Topical ketoconazole products such as creams and shampoos have their own storage requirements. Cream formulations should be stored at room temperature and kept in their original tubes with caps tightly closed. Ketoconazole shampoo should also be stored at room temperature and kept in its original container. These topical products should not be frozen. After use, containers should be closed securely to prevent contamination and drying. Expiration dates should be observed, and products should be discarded if they appear discolored, have an unusual odor, or show other signs of degradation.

Safe storage of ketoconazole in households with pets and children is important. Oral tablets should be stored in child-resistant containers and kept in locations that pets and children cannot access, such as high cabinets with secure closures. While ketoconazole tablets are not typically flavored in a way that attracts dogs, all medications should be stored securely to prevent accidental ingestion. Overdose with ketoconazole could result in severe gastrointestinal upset and potentially liver damage. When dispensing doses, only the amount needed should be removed, and the container should be immediately returned to secure storage. Any dropped tablets should be retrieved promptly.

Proper disposal of unused or expired ketoconazole protects the environment and prevents accidental exposure. Medications should not be flushed down the toilet or poured down drains. Many communities have drug take-back programs that accept unused medications; veterinary clinics may also participate in take-back programs. If no take-back option is available, the FDA recommends mixing the medication with an undesirable substance such as coffee grounds or cat litter, placing it in a sealed container, and disposing of it in household trash with personal information removed from the label. Topical products should be disposed of similarly, ensuring tubes are emptied and crushed before disposal. Questions about proper disposal can be directed to the veterinarian or pharmacist.

Most dog breeds tolerate ketoconazole when the medication is used at appropriate doses with proper monitoring, though individual variation in drug tolerance exists. No specific breed-related contraindications have been definitively established for ketoconazole in dogs. However, certain breeds may be more prone to the conditions that ketoconazole treats, and some may have characteristics that warrant additional consideration during treatment. Veterinarians consider breed along with other patient factors when developing treatment plans and monitoring protocols.

Breeds predisposed to Malassezia dermatitis may be more likely to receive ketoconazole therapy. West Highland White Terriers, Basset Hounds, Cocker Spaniels, English Setters, Shih Tzus, and Dachshunds are among the breeds with higher incidence of Malassezia skin infections. These breeds often have underlying allergic skin disease or conformational features that promote yeast overgrowth. Dogs of these breeds receiving ketoconazole for recurrent Malassezia infections should also have underlying causes investigated and addressed to prevent continuous need for antifungal therapy.

Dogs carrying the MDR1 (ABCB1) gene mutation warrant consideration when ketoconazole is prescribed, primarily due to potential drug interactions rather than direct sensitivity to ketoconazole itself. Ketoconazole can increase blood levels of medications that are P-glycoprotein substrates, which could be problematic in MDR1-mutant dogs also receiving ivermectin or similar drugs. Breeds commonly affected by the MDR1 mutation include Collies, Australian Shepherds, Shetland Sheepdogs, Old English Sheepdogs, Border Collies, Long-haired Whippets, Silken Windhounds, and mixed breeds with herding dog heritage. Genetic testing can identify dogs carrying this mutation.

Size-based dosing considerations apply to ketoconazole as they do to other medications. Toy breeds require careful dose calculation, and the 200 mg tablet size may need to be divided for accurate dosing in very small dogs. Giant breeds require larger numbers of tablets, which has implications for treatment cost. The veterinarian will determine the most practical approach for dogs of different sizes. Age-related considerations also apply across all breeds. Senior dogs may have decreased liver function that increases the risk of hepatotoxicity and may warrant more frequent monitoring. Young puppies have immature hepatic function and may be more susceptible to adverse effects. The veterinarian considers age and overall health status when determining whether ketoconazole is appropriate and what monitoring is needed.

Several alternative antifungal medications are available for treating fungal and yeast infections in dogs, and veterinarians may choose among these based on the specific condition, efficacy profiles, safety considerations, cost, and individual patient factors. Itraconazole (Sporanox) is a triazole antifungal that has largely supplanted ketoconazole for many indications due to its broader spectrum of activity, greater potency, and improved safety profile. Itraconazole is generally preferred for systemic fungal infections such as blastomycosis, histoplasmosis, and cryptococcosis, and is also effective for dermatophytosis and Malassezia infections. However, itraconazole is typically more expensive than ketoconazole.

Fluconazole is another triazole antifungal that may be used as an alternative to ketoconazole in certain situations. Fluconazole has excellent penetration into the central nervous system and eye, making it particularly useful for cryptococcosis with CNS involvement or coccidioidomycosis (Valley Fever). Unlike ketoconazole, fluconazole does not require an acidic stomach for absorption. However, fluconazole has poor activity against dermatophytes and Aspergillus species and is generally not effective for Malassezia infections, limiting its utility as a direct ketoconazole substitute for these conditions.

Terbinafine (Lamisil) is an allylamine antifungal with a different mechanism of action than the azoles. It has become a popular alternative for treating dermatophytosis in dogs and has some activity against Malassezia, though it is not typically first-line for yeast infections. Terbinafine does not have the hormonal side effects associated with ketoconazole and has a generally favorable safety profile. Griseofulvin is an older antifungal that remains effective for dermatophytosis but has no activity against Malassezia or systemic fungal infections.

Topical antifungal products are often used alongside or instead of systemic therapy for localized infections. Topical ketoconazole products including shampoos and creams can be effective for mild Malassezia infections without requiring systemic medication. Miconazole-chlorhexidine shampoos provide antifungal and antibacterial activity for skin infections. For ear infections, topical antifungal ear preparations may be sufficient without systemic therapy. The veterinarian may recommend topical treatment alone for mild or localized infections or in combination with systemic therapy for more severe or widespread disease. Any changes to antifungal therapy should be made under veterinary guidance.